Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 772-778

  Madajewicz, Stefan ^a   Waterhouse, David M ^b   Ritch, Paul S ^c   Khan, M Qaseem ^d   Higby, Donald J ^e   Leichman, Cynthia G ^f   Malik, Sandeep K ^a   Hentschel, Patricia ^g   Gill, John F ^h   Zhao, Luping ^h   Nicol, Steven J ^h  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b Oncology Hematology Care Inc   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d MARSHFIELD CLINIC   (United States)

^e BAYSTATE MEDICAL CENTER   (United States)

^f Immunology and Medical Genetics   (United States)

^g Stony Brook School of Dental Medicine   (United States)

^h Lilly USA   (United States)

Author keywords

Advanced colorectal cancer; Bevacizumab; FFG; FOLFOX4; Phase II trial; Randomize

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BRAIN INFARCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; CRANIAL NEUROPATHY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOXIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERIRECTAL ABSCESS; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; RECTUM DISEASE; SENSORY NEUROPATHY; SMALL INTESTINE OBSTRUCTION; SUBDURAL HEMATOMA; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; ADENOCARCINOMA; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METASTASIS; MORTALITY; PATHOLOGY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84862274484     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9598-9     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics 2008. CA Cancer J Clin 58:71-96. doi:10.3322/CA.2007.0010
2. Kelly C, Cassidy J (2007) Chemotherapy in metastatic colorectal cancer. Surg Oncol 16:65-70. doi:10.1016/j.suronc.2007.04.006
3. Sabharwal A, Kerr D (2007) Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev Anticancer Ther 7:477-487. doi:10.1586/14737140.7.4.477
4. Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755
5. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914. doi:10.1056/NEJM200009283431302
6. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30. doi:10.1200/JCO.2004.09.046
7. Díaz-Rubio E, Sastre J, Zaniboni A et al (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9:105-108. doi:10.1023/A:1008200825886
8. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
9. Merriman RL, Hertel LW, Schultz RM et al (1996) Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 14:243-247. doi:10.1007/BF00194526
10. Moore DF Jr, Pazdur R, Daugherty K et al (1992) Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 10:323-325. doi:10.1007/BF00944189
11. Abbruzzese J, Pazdur R, Ajani J et al (1991) A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 10: (abstr 456)
12. Poplin E, Roberts J, Tombs M et al (1999) Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Invest New Drugs 17:57-62. doi:10.1023/A: 1006239200772
13. Tampellini M, Tucci M, Saini A et al (2003) Weekly gemcitabine plus protracted continuous infusion of 5 fluorouracil as third line chemotherapy in advanced colorectal cancer patients. Proc Am Soc Clin Oncol 22: (abstr 1466).
14. Pachon V, Garcia-Alfonso P, Iglesias L et al (2005) Gemcitabine plus continuous infusion of 5-FU for heavily pretreated advanced colorectal cancer patients; phase I/II study. Proc Am Soc Clin Oncol 23: (abstr 3735)
15. Madajewicz S, Hentschel P, Burns P et al (2000) Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol 18:3553-3557
16. Giachetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147
17. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543. doi:10.1007/s001099900019
18. Hurwitz H, Fehrenbacher L, Novotny Wet al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. doi:10.1056/NEJMoa032691
19. Hedrick EE, Hurwitz H, Sarkar S et al (2004) Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 22:249s, suppl; abstr 3517
20. Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 16:3706-3712. doi:10.1200/JCO.2005.00.232
21. National Cancer Institute: FDA approval for bevacizumab. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab#Anchor-Approva- 23287. Accessed 18 October 2009
22. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216. doi:10.1093/jnci/92.3.205
23. National Cancer Institute: National Cancer Institute Common Toxicity Criteria Version 2.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcv20-4-30-992.pdf. Accessed 18 October 2009
24. Kaplan E, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-81. doi:10.2307/2281868
25. Bland JM, Altman DG (2004) The logrank test. BMJ 328:1073
26. André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351. doi:10.1056/NEJMoa032709
27. Grothey A, Hendrick EE, Mass RD et al (2008) Response-independed survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Onc 26:183-189